This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to the pharmaceutical company Glaxosmithkline, LLC to provide pediatric influenza vaccines for the 2024-2025 timeframe. The contract has a ceiling value of $182,592,000 and a period of performance through February 28, 2025.
Glaxosmithkline, a foreign-owned for-profit organization, has extensive experience as a prime contractor providing a range of pharmaceutical products and services to federal agencies, including influenza and other vaccines, antiviral medications, and vaccine adjuvants. This IDC is one of several federal contract vehicles held by Glaxosmithkline, which also includes multiple award IDCs with the CDC and VA for influenza vaccines and vaccine storage/rotation services. The contracted pediatric influenza vaccines will support the CDC's routine immunization programs and public health requirements, with specific quantities and delivery timelines established through associated task orders. Glaxosmithkline will likely perform the work at its North Carolina facilities under this firm fixed price contract, which does not include any set-aside designations.
Generated 10/22/24, 9:04 AM